Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q2 earnings results on Wednesday, August 13th, after market close. The consensus EPS Estimate is -$0 ...

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

NEW YORK - August 12, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, shares practical ways clinical teams can strengthen trial ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...

In this video interview, Meri Beckwith, Co-CEO of Lindus Health, discusses recent Complete Response Letters issued to Replimune and Capricor, explaining how shifts in FDA reviewers can affect ...

I hope the new FDA, which is the old FDA with newer understanding of President Trump’s expectations, will reembrace that spirit of right to try and the taking of a machete to the red tape that must be ...

At 05:45 a.m. ET, Dow E-minis were up 98 points, or 0.22%, with 7,922 contracts changing hands, S&P 500 E-minis were up 6.25 ...

The panel’s reinstatement is one of a series of controversial moves made by Robert F. Kennedy Jr. to put vaccines under new ...